As Calavo Growers (CVGW) Share Value Rose, Shareholder Ranger Investment Management LP Has Lowered Holding by $2.20 Million; Gilead (GILD) Share Value Rose While Busey Trust Company Has Lowered by $1.31 Million Its Position

April 22, 2018 - By Darrin Black

Calavo Growers, Inc. (NASDAQ:CVGW) Logo

Busey Trust Company decreased its stake in Gilead (GILD) by 26.2% based on its latest 2017Q4 regulatory filing with the SEC. Busey Trust Company sold 18,456 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 51,980 shares of the health care company at the end of 2017Q4, valued at $3.72M, down from 70,436 at the end of the previous reported quarter. Busey Trust Company who had been investing in Gilead for a number of months, seems to be less bullish one the $96.09B market cap company. The stock decreased 0.99% or $0.74 during the last trading session, reaching $73.7. About 4.23M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since April 22, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Ranger Investment Management Lp decreased its stake in Calavo Growers Inc. (CVGW) by 4.4% based on its latest 2017Q4 regulatory filing with the SEC. Ranger Investment Management Lp sold 26,183 shares as the company’s stock rose 15.31% while stock markets declined. The institutional investor held 569,166 shares of the consumer non-durables company at the end of 2017Q4, valued at $48.04M, down from 595,349 at the end of the previous reported quarter. Ranger Investment Management Lp who had been investing in Calavo Growers Inc. for a number of months, seems to be less bullish one the $1.68B market cap company. The stock decreased 2.05% or $2 during the last trading session, reaching $95.55. About 105,439 shares traded. Calavo Growers, Inc. (NASDAQ:CVGW) has risen 52.39% since April 22, 2017 and is uptrending. It has outperformed by 40.84% the S&P500.

Busey Trust Company, which manages about $783.20M US Long portfolio, upped its stake in Microsoft Corporation (NASDAQ:MSFT) by 6,148 shares to 308,149 shares, valued at $26.36M in 2017Q4, according to the filing. It also increased its holding in Wal Mart (NYSE:WMT) by 5,991 shares in the quarter, for a total of 17,381 shares, and has risen its stake in Vanguard (VCIT).

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 126 analyst reports since July 29, 2015 according to SRatingsIntel. Credit Suisse maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, September 14 with “Outperform” rating. The company was maintained on Wednesday, February 7 by BMO Capital Markets. The stock has “Strong Buy” rating by Jyske Bank on Thursday, September 10. The company was maintained on Wednesday, October 4 by Jefferies. J.P. Morgan maintained the stock with “Buy” rating in Monday, July 24 report. The company was initiated on Thursday, September 22 by Berenberg. UBS maintained it with “Buy” rating and $118 target in Friday, April 29 report. Jefferies maintained the stock with “Hold” rating in Wednesday, August 31 report. The rating was maintained by Maxim Group on Thursday, July 27 with “Hold”. The firm earned “Buy” rating on Wednesday, June 1 by Gabelli.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on May, 1 after the close. They expect $1.59 earnings per share, down 27.73% or $0.61 from last year’s $2.2 per share. GILD’s profit will be $2.07 billion for 11.59 P/E if the $1.59 EPS becomes a reality. After $1.60 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -0.63% negative EPS growth.

Since January 2, 2018, it had 0 insider buys, and 18 selling transactions for $39.95 million activity. 5,000 shares were sold by Washington Robin L, worth $401,566. $2.09M worth of stock was sold by Alton Gregg H on Thursday, February 1. 100,000 Gilead Sciences, Inc. (NASDAQ:GILD) shares with value of $8.02 million were sold by Meyers James R. WILSON GAYLE E also sold $4.68M worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares. MARTIN JOHN C sold $3.66M worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Monday, April 2.

Investors sentiment decreased to 0.8 in 2017 Q4. Its down 0.23, from 1.03 in 2017Q3. It fall, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Toth Advisory Corp invested in 0% or 137 shares. Union Bank Corp has invested 0.07% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Cornerstone Cap Incorporated has invested 0.77% in Gilead Sciences, Inc. (NASDAQ:GILD). B And T Mngmt Dba Alpha Mngmt has 33,038 shares for 1.12% of their portfolio. Putnam Fl Mgmt owns 20,211 shares. Covington Mgmt reported 0.18% in Gilead Sciences, Inc. (NASDAQ:GILD). Welch And Forbes Lc accumulated 157,596 shares. Coastline reported 11,125 shares. Payden & Rygel owns 251,600 shares. Schafer Cullen Capital invested 0% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Lombard Odier Asset Mngmt (Europe) Limited reported 0.07% stake. Norinchukin Commercial Bank The invested in 171,334 shares or 0.21% of the stock. Cornerstone Advsr has 0.36% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 44,000 shares. 203,135 were accumulated by Marco Investment Mgmt Ltd Liability Corporation. Maryland-based Fulton Breakefield Broenniman Lc has invested 0.98% in Gilead Sciences, Inc. (NASDAQ:GILD).

Since December 26, 2017, it had 0 insider purchases, and 4 insider sales for $2.17 million activity. Another trade for 1,000 shares valued at $85,050 was sold by Brown Marc Laurence. LEAVENS J LINK sold $692,333 worth of stock. The insider Gibson James E sold 10,000 shares worth $791,400.

Analysts await Calavo Growers, Inc. (NASDAQ:CVGW) to report earnings on June, 5. They expect $0.84 EPS, up 13.51% or $0.10 from last year’s $0.74 per share. CVGW’s profit will be $14.73M for 28.44 P/E if the $0.84 EPS becomes a reality. After $0.54 actual EPS reported by Calavo Growers, Inc. for the previous quarter, Wall Street now forecasts 55.56% EPS growth.

Among 5 analysts covering Calavo Growers (NASDAQ:CVGW), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Calavo Growers had 19 analyst reports since August 24, 2015 according to SRatingsIntel. On Wednesday, December 21 the stock rating was maintained by Lake Street with “Buy”. The stock of Calavo Growers, Inc. (NASDAQ:CVGW) earned “Overweight” rating by Stephens on Monday, August 24. DA Davidson upgraded Calavo Growers, Inc. (NASDAQ:CVGW) rating on Thursday, January 7. DA Davidson has “Buy” rating and $58.0 target. The firm earned “Buy” rating on Thursday, September 8 by Lake Street. The stock of Calavo Growers, Inc. (NASDAQ:CVGW) has “Buy” rating given on Friday, August 18 by Buckingham Research. The rating was maintained by Buckingham Research with “Buy” on Thursday, March 8. The rating was maintained by Lake Street on Wednesday, December 30 with “Buy”. The firm has “Overweight” rating by Stephens given on Friday, November 11. Vetr downgraded the stock to “Buy” rating in Wednesday, August 26 report. As per Monday, October 19, the company rating was initiated by Buckingham Research.

Calavo Growers, Inc. (NASDAQ:CVGW) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts